POTASSIUM CHLORIDE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Labs Fl Inc	POTASSIUM CHLORIDE	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	077419	ANDA	AvKARE	42291-679-50	500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (42291-679-50)	2013-03-05
Actavis Labs Fl Inc	POTASSIUM CHLORIDE	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	077419	ANDA	Actavis Pharma, Inc.	62037-559-01	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (62037-559-01)	2008-08-25
Actavis Labs Fl Inc	POTASSIUM CHLORIDE	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	077419	ANDA	Actavis Pharma, Inc.	62037-559-05	500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (62037-559-05)	2008-08-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 23, 2026

Potassium chloride (KCl) is a widely sourced commodity-active ingredient used across oral solid and liquid formulations and as an IV replacement/supplement in hospital settings. In practice, the supplier base is dominated by large specialty chemical and commodity bulk manufacturers with downstream GMP pharmaceutical sites for oral and injectable grades, plus regional contract manufacturers that fill/finish finished dosage forms (solutions, tablets, capsules, powders, effervescent products).

Because KCl is not patented as a single “drug product” in the way novel APIs are, supply questions typically resolve to: (1) which firms offer pharmaceutical-grade KCl with the right particle size and impurity specs, (2) which sites hold current GMP registrations for injectable or oral grades, and (3) which suppliers can sustain volumes through sulfate/chloride salt market cycles, shipping constraints, and inspection/registration shocks.

Who supplies pharmaceutical-grade potassium chloride (KCl) API for tablets and oral liquids?

Primary global supplier archetypes

Pharmaceutical-grade potassium chloride sourcing typically comes from:

Bulk chemical producers with GMP pharmaceutical API sites (oral and injectable grades).
Specialty salts manufacturers that supply regulated markets through documented quality systems, controlled impurity profiles, and batch traceability.
API-to-finished-form integrators where the same group supplies both KCl API and the finished oral dosage form (direct tablet/capsule manufacturing).

Common qualification requirements buyers apply

For KCl API used in oral solids and oral liquids, purchasers typically validate:

Compendial compliance (USP/EP/BP depending on target market).
Impurity limits (notably sodium content, insoluble matter, sulfate, magnesium, heavy metals).
Particle size distribution where relevant to dissolution and blend uniformity.
Stability and moisture control for effervescent and high-throughput granulation processes.
Supply continuity and change control for source location, crystallization process, and packaging format.

Which companies are typically in the pharmaceutical KCl supplier set?

The pharmaceutical KCl supplier universe generally includes globally scaled inorganic chemical/salts manufacturers and their regional GMP affiliates. Public-facing procurement catalogs and industry databases repeatedly show supply from large producers of potassium salts (including KCl) that maintain regulated quality systems.

Typical supplier list for pharma-grade KCl (global large-scale producers and regulated-supply affiliates):

The Mosaic Company (potash producer supplying potassium salts into regulated markets through downstream channels).
Uralkali (potash producer with global sales footprint that often supplies bulk KCl for industrial and regulated channels, subject to qualification).
K+S Aktiengesellschaft (potash and inorganic salts supplier with global reach and multi-market distribution structures).
OCP Group (Morocco-based phosphate and potash value chain; potash-related inorganic salts supply presence).
Compass Minerals / related salt producers (where they have regulated-supply capability in inorganic salts categories).
Regional chemical salts suppliers that supply USP/EP-grade KCl via contracted GMP packaging, testing, and labeling.

Note: Potassium chloride supply chains for pharma are frequently routed through distributors or contract testing/rep processing. Final qualification often rests on GMP site registration status and batch-level certificates, not only on brand recognition.

Who supplies potassium chloride for injectable use (IV replacement) and hospital infusions?

What makes injectable KCl harder to source

Injectable-grade KCl requires tighter control and documentation:

Sterility assurance and endotoxin control for solutions, depending on whether the supplier provides sterile filled presentations or API-only.
Container closure system validation (for ampoules, vials, pharmacy bulk packages).
Source traceability with impurity profiles aligned to injection standards.
Manufacturing controls for chloride spec, metals, and water quality.

Supplier categories for injectable KCl

Buyers usually find three supply models:

KCl sterile solution product manufacturers (they provide the finished infusion concentrate or ready-to-dilute solutions).
Sterile compounding or fill-finish contractors that fill KCl solutions supplied as bulk drug substance.
API suppliers supplying pharmaceutical-grade KCl for manufacturers that produce the injection themselves.

What to look for in supplier capability

Whether the supplier holds GMP manufacturing for injection-grade KCl or provides sterile fill-finish under a recognized quality system.
Whether the supplier’s site is inspected and cleared for regulated injectable manufacture in target geographies (FDA/EMA-aligned regimes).

Which companies provide KCl for pharmacy compounding vs commercial finished dosage forms?

Compounding supply differs from commercial supply

Compounding settings more frequently purchase:

Pharmaceutical KCl powder/solid with documented compendial grade and consistent impurity profile.
Smaller packaging sizes with faster lot turnaround.

Commercial finished products purchase:

Higher-volume GMP supply with validated processes for blend, granulation, tablet compression, capsule filling, or solution formulation.

Supplier reality

Where the same top-tier producer supplies pharma-grade KCl, the actual buyer interface is often:

A US/EU distributor with storage and repack/labeling compliance.
A contract packager delivering to finished-product sites or compounding wholesalers.

What patents protect potassium chloride (KCl) as a drug product, and how does that affect suppliers?

Potassium chloride as an active ingredient is generally treated as a known, compendial salt. Patent barriers typically do not block access to the API across the same breadth as novel molecular entities. The supplier landscape is therefore driven by regulatory qualification, GMP capacity, and compendial compliance rather than by active patent exclusivity on the salt itself.

Resulting impact on supplier strategy: procurement and partnership decisions focus on site approvals, impurity spec control, audit outcomes, and continuity of manufacturing capacity.

How strong are regulatory and quality barriers for switching potassium chloride suppliers?

Key switching friction points

Analytical method alignment: suppliers use company methods; buyers need method comparability for key release tests.
Impurity drift risk: minor shifts in raw material sources or crystallization conditions can trigger out-of-spec results.
Moisture and particle size variability: impacts blend uniformity and dissolution for oral products.
Change control: QA requires stability data and bridging batches for new suppliers.

Most common switch mitigation

Qualification via side-by-side stability on representative formulations.
Bridging batch release using buyer’s finished-product acceptance criteria.
Auditing manufacturing and packaging steps, especially for injectable-grade candidates.

Where does KCl supply risk concentrate (shipping, raw potash, and geopolitical exposure)?

Potassium chloride supply is ultimately tied to potash production and logistics. Risk tends to concentrate in:

Potash market cycles affecting KCl pricing and availability.
Regional shipping constraints for bulk chemicals.
Inspection and GMP disruptions at major manufacturing sites.
Sanctions and trade restrictions for certain potash producers in some jurisdictions.

Procurement strategies typically diversify by:

Multiple qualified sources with documented impurity profiles.
Distributor redundancy (alternative wholesalers and secondary channels).
Pre-positioning critical inventory ahead of seasonal demand.

What is the Orange Book status of potassium chloride products, and does it create supplier lock-in?

Potassium chloride products are generally not tied to blockbuster exclusivity structures like new chemical entity (NCE) drugs. Instead, they are typically compendial and therefore governed by:

Drug listing practices rather than exclusivity blocking generics of an API.
Product-specific controls for a formulation (for example, extended-release or specialty delivery forms), which can affect which finished-product manufacturers are in play, but not the underlying ability to source KCl.

Supplier lock-in is therefore more often linked to:

Finished-product GMP and distribution contracts
Supplier qualification status than to Orange Book exclusivity.

How do KCl supplier costs and quality compare across bulk API vs finished dosage form outsourcing?

Cost structure

Bulk API purchase cost is usually lower than buying finished dosage form.
Finished-form outsourcing shifts cost toward:
- GMP fill-finish, packaging, and distribution
- Regulatory release and stability testing
- Inventory turns and supply chain lead times

Quality structure

Bulk API suppliers control impurity and particle specs at the API stage.
Finished-form manufacturers control dissolution, content uniformity, and sterility assurance depending on dosage form.

Procurement decisions typically balance:

Reliability of API spec consistency versus
Reliability of final dosage form batch performance.

Which contract manufacturers handle KCl formulations (oral solids, oral liquids, and sterile solutions)?

Oral solids

KCl is commonly formulated as:

Immediate-release tablets
Capsules (in some markets)
Effervescent or powder sachets in some regional offerings

Contract manufacturers for these dosage forms tend to be:

Established oral solid dosage CDMOs with GMP facilities
Regional dose-form specialists handling compendial salts at scale

Oral liquids

KCl oral solutions and syrups require:

Controlled water activity management
Microbial control strategies appropriate to solution pH and excipient package

Sterile solutions

For injection, contract manufacturers require:

Sterile production capacity and validation
Batch-level traceability to KCl API (if API is supplied by customer)

Key Takeaways

Potassium chloride (KCl) supply for pharmaceuticals is a qualification-driven market centered on GMP capability and compendial/spec compliance, not on patent exclusivity of the API.
Supplier switching risk is mainly driven by impurity profile drift, particle size/moisture effects for oral forms, and sterility/endpoint controls for injectable-grade supply.
The global supplier set is dominated by large potash and inorganic salts producers with regulated downstream supply channels, with distributors and contract packagers commonly mediating the buyer interface.

FAQs

1) What specs matter most when qualifying potassium chloride API for oral tablets?

Impurity limits (including sodium, sulfate, magnesium), insoluble matter, heavy metals, and particle size/moisture behavior that affect dissolution and blend uniformity.

2) Can one qualify injectable potassium chloride using the same supplier as oral KCl?

Often no, because injectable-grade supply requires additional controls and typically tighter documentation around impurity profiles and sterile manufacturing chain-of-custody.

3) Do potassium chloride shortages affect finished product more than raw material?

Finished products can be more impacted because GMP release, fill-finish capacity, and distribution contracts can bottleneck even when bulk KCl is available.

4) What documentation do buyers require for KCl lot release?

Certificates of analysis with batch traceability, compendial compliance data, impurity profiles, and stability or change-control history aligned to the buyer’s quality system.

5) How do distributors change the risk profile for KCl supply?

Distributors can reduce lead time variance but add an extra handling and packaging layer; buyers typically re-qualify packaging integrity and relabeling controls.

References

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
European Medicines Agency. (n.d.). Medicines. EMA.
U.S. Pharmacopeia. (n.d.). Potassium Chloride monographs (USP). USP.
European Pharmacopoeia. (n.d.). Potassium chloride monographs (Ph. Eur.). European Directorate for the Quality of Medicines & HealthCare.

Suppliers and packagers for generic pharmaceutical drug: POTASSIUM CHLORIDE